title: Yttrium-based therapy for neuroendocrine tumors.
abstract: Peptide receptor radionuclide therapy with (90)Y-peptides is generally well tolerated. Acute side effects are usually mild; some are related to the coadministration of amino acids and others to the radiopeptide itself. Chronic and permanent effects on target organs, particularly kidneys and bone marrow, are generally mild if necessary precautions are taken. The potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumor masses are irradiated with adequate doses, volume reduction may be observed. (90)Y-octreotide has been the most used radiopeptide in the first 8 to 10 years of experience.
authors.affiliation: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Lisa
authors.initials: L
authors.lastname: Bodei
authors.affiliation: Division of Medical Physics, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Cremonesi
authors.affiliation: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. Electronic address: divisione.medicinanucleare@ieo.it.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganelli
mesh_terms: D001855:Bone Marrow Diseases / Q000517:prevention & control; D006801:Humans; D007674:Kidney Diseases / Q000517:prevention & control; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058958:Organs at Risk / Q000528:radiation effects; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D016896:Treatment Outcome
chemical_list: D011837:Radiation-Protective Agents; D019275:Radiopharmaceuticals; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide
keywords: (90)Y-DOTATOC; Dosimetry; Neuroendocrine tumors; PRRT; Peptide receptor radionuclide therapy